Article Text

Download PDFPDF
Development of comprehensive disease assessment in systemic vasculitis
  1. Oliver Flossmann1,
  2. Paul Bacon2,
  3. Kirsten de Groot3,
  4. David Jayne4,
  5. Niels Rasmussen5,
  6. Philip Seo6,
  7. Kerstin Westman7,
  8. Raashid Luqmani1
  1. 1Botnar Research Centre, University of Oxford, Oxford, UK
  2. 2Department of Rheumatology, University of Birmingham, Birmingham, UK
  3. 3Department of Nephrology, University of Lubeck, Lubeck, Germany
  4. 4Department of Nephrology, Addenbrooke’s Hospital, Cambridge, UK
  5. 5Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark
  6. 6Vasculitis Center, Johns Hopkins University, Baltimore, Maryland, USA
  7. 7Department of Nephrology, University of Malmo, Malmo, Sweden
  1. Correspondence to:
    Dr R Luqmani
    Department of Rheumatology, Nuffield Orthopaedic Centre, Windmill Road, Oxford OX3 7LD, UK; raashid.luqmani{at}


The systemic vasculitides are multisystem disorders with considerable mortality and morbidity and frequent relapses. In the absence of reliable serological markers, accurate clinical tools are required to assess disease activity and damage for treatment decisions, and for the performance of clinical trials. This article reviews and summarises the development and use of disease assessment tools for determining activity and damage in systemic vasculitis and reports ongoing initiatives for further development of disease assessment tools. A literature search was conducted using PubMed and reference lists for vasculitis, assessment, clinical trials, outcome and prognosis. The findings indicate that comprehensive disease assessment in vasculitis requires documentation of disease activity, chronic irreversible damage and impairment of function.

  • ANCA, antineutrophil cytoplasmic antibody
  • BVAS, Birmingham Vasculitis Activity Score
  • BVAS/WG, Birmingham Vasculitis Activity Score for Wegener’s granulomatosis
  • DEI, Disease Extent Index
  • EUVAS, European Vasculitis Study Group
  • FFS, Five Factor Score
  • ITU, intensive treatment unit
  • OMERACT, Outcome Measures for Arthritis Clinical Trials
  • VDI, Vasculitis Damage Index

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 25 May 2006

  • Competing interests: None